Ganglioglioma-induced animal model and a method for diagnosing and treating ganglioglioma and related diseases
AssigneesKorea Advanced Institute of Science and Technology, Yonsei University, University—Industry Foundation (Uif)
InventorsJeong Ho Lee, Hyun Yong Koh, Dong Seok Kim
Life of this patent
Estimating the term…
Abstract
The present invention relates to a biomarker of epilepsy, a composition for diagnosing epilepsy, an epilepsy-induced animal, and a composition for preventing or treating epilepsy, and specifically, relates to a composition for diagnosing epilepsy comprising a BRAF mutant protein and a nucleic acid molecule, and an agent capable of detecting the protein or nucleic acid molecule, an epilepsy-induced animal transformed with the BRAF mutant nucleic acid molecule, and a composition for prevention or treatment of epilepsy comprising a BRAF mutant protein activity inhibitor.
Claims5
A murine model with ganglioglioma or epilepsy caused by ganglioglioma, wherein the animal model is prepared by obtaining an embryo from a conditional mutant transgenic animal including a nucleic acid molecule encoding a BRAF mutant protein and inducing expression of the BRAF mutant protein or the nucleic acid molecule encoding the BRAF mutant protein in neural progenitor cells of lateral ventricle of the embryo at embryonic day 14 (E14), wherein the BRAF mutant protein consisting of an amino acid sequence comprising a mutation in which valine at position 600 is substituted to glutamic acid in an amino acid sequence of SEQ ID NO:
- 1, or a BRAF mutant protein consisting of an amino acid sequence comprising a mutation in which valine at position 637 is substituted to glutamic acid in an amino acid sequence of SEQ ID NO:
- 3, and wherein the animal model has characteristics of activated MARK signaling pathway of Ras-Raf-MEK-ERK, dysplasia of nerve cells, and malformation of cortical development.
Dependencies are inferred from the claim text.